• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

    11/13/24 4:48:49 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRVI alert in real time by email
    SC 13G/A 1 d873306dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Maravai LifeSciences Holdings, Inc.

    (Name of Issuer)

    Class A Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    56600D 107

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    1.   

    Names of Reporting Persons

     

    Maravai Life Sciences Holdings 2, LLC

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    20,150,005

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    20,150,005

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    20,150,005

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    7.98%(1)

    12.   

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)

    Calculated based on 141,843,505 shares of the Issuer’s Class A common stock, par value $0.01 per share (“Class A Common Stock”), outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 units of Maravai Topco Holdings, LLC (“Common Units”) (together with an equal number of shares of the Issuer’s Class B common stock, par value $0.01 per share (“Class B Common Stock”)).


    1.   

    Names of Reporting Persons

     

    Maravai Life Sciences Holdings, LLC

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    110,684,080

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    110,684,080

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    110,684,080(1)

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    43.83%(2)

    12.   

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)

    Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

    (2)

    Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    1.   

    Names of Reporting Persons

     

    GTCR Fund XI/C LP

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    20,150,005

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    20,150,005

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    20,150,005

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    7.98%(1)

    12.   

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)

    Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    1.   

    Names of Reporting Persons

     

    GTCR Fund XI/B LP

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    110,684,080

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    110,684,080

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    110,684,080(1)

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    43.83%(2)

    12.   

    Type of Reporting Person (See Instructions)

     

    PN

    (1) Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

    (2) Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    1.   

    Names of Reporting Persons

     

    GTCR Co-Invest XI LP

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    110,684,080

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    110,684,080

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    110,684,080(1)

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    43.83%(2)

    12.   

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)

    Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

    (2)

    Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    1.   

    Names of Reporting Persons

     

    GTCR Partners XI/A&C LP

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    20,150,005

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    20,150,005

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    20,150,005

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    7.98%(1)

    12.   

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)

    Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    1.   

    Names of Reporting Persons

     

    GTCR Partners XI/B LP

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    110,684,080

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    110,684,080

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    110,684,080(1)

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    43.83%(2)

    12.   

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)

    Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

    (2)

    Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    1.   

    Names of Reporting Persons

     

    GTCR Investment XI LLC

    2.   

    Check The Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned By Each Reporting Person

    With

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    130,834,085

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    130,834,085

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    130,834,085(1)

    10.   

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented By Amount in Row (9)

     

    51.81%(2)

    12.   

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)

    Includes 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).

    (2)

    Calculated based on 141,843,505 shares of Class A Common Stock outstanding as of November 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, as increased by an additional 110,684,080 shares of Class A Common Stock issuable in exchange for 110,684,080 Common Units (together with an equal number of shares of Class B Common Stock).


    Item 1(a).

    Name of Issuer

    Maravai LifeSciences Holdings, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of the Issuer’s Principal Executive Offices

    10770 Wateridge Circle, Suite 200

    San Diego, CA 92121

     

    Item 2(a).

    Names of Persons Filing

    This Amendment No. 3 to Schedule 13G is being jointly filed by the entities and persons listed below, each of which are collectively referred to herein as the “Reporting Persons”:

     

      (i)

    Maravai Life Sciences Holdings 2, LLC (“MLSH 2”)

     

      (ii)

    Maravai Life Sciences Holdings, LLC (“MLSH 1” and collectively with MLSH 2, the “MLSH Entities”)

     

      (iii)

    GTCR Fund XI/C LP

     

      (iv)

    GTCR Fund XI/B LP

     

      (v)

    GTCR Co-Invest XI LP

     

      (vi)

    GTCR Partners XI/A&C LP

     

      (vii)

    GTCR Partners XI/B LP

     

      (viii)

    GTCR Investment XI LLC

    The Reporting Persons previously entered into an Agreement Regarding the Joint Filing of Schedule 13G, dated February 11, 2021, pursuant to which the Reporting Persons agreed to file the Schedule 13G and any amendments thereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

     

    Item 2(b).

    Address of the Principal Business Office, or if none, Residence

    c/o GTCR, LLC

    300 North LaSalle Street, Suite 5600

    Chicago, IL 60654

     

    Item 2(c).

    Citizenship

    See responses to Item 4 on each cover page.

     

    Item 2(d).

    Title of Class of Securities

    Class A common stock, par value $0.01 per share.

     

    Item 2(e).

    CUSIP Number

    56600D 107

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a (n):

    Not Applicable

     

    Item 4.

    Ownership

     

      (a)

    Amount beneficially owned:

    See responses to Item 9 on each cover page.

     

      (b)

    Percent of Class:

    See responses to Item 11 on each cover page.


      (c)

    Number of shares as to which the Reporting Person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See responses to Item 5 on each cover page.

     

      (ii)

    Shared power to vote or to direct the vote:

    See responses to Item 6 on each cover page.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See responses to Item 7 on each cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See responses to Item 8 on each cover page.

    Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, MLSH 1 is entitled at its option to exchange Common Units (together with an equal number of shares of Class B Common Stock) for shares of Class A Common Stock on a one-for-one basis. MLSH 1 directly holds 110,684,080 Common Units and MLSH 2 directly holds 20,150,005 shares of Class A Common Stock.

    MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP controls the board of managers of MLSH 2. GTCR Fund XI/B LP and GTCR Co-Invest XI LP control the board of managers of MLSH 1. GTCR Partners XI/A&C LP is the general partner of GTCR Fund XI/C LP. GTCR Partners XI/B LP is the general partner of GTCR Fund XI/B LP. GTCR Investment XI LLC is the general partner of each of GTCR Co-Invest XI LP, GTCR Partners XI/A&C LP and GTCR Partners XI/B LP. GTCR Investment XI LLC is managed by a board of managers (the “GTCR Board of Managers”) consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the shares of Class A Common Stock held directly by MLSH 2 and MLSH 1, respectively. Each of GTCR Partners XI/A&C LP, GTCR Investment XI LLC and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A Common Stock held of record by MLSH 2, and each of GTCR Partners XI/B LP, GTCR Investment XI LLC and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares of Class A Common Stock held of record by MLSH 1 and MLSH 2 and this statement shall not be construed as an admission that any of such individual members or any of the Reporting Persons are, for purposes of Section 13(d) or 13(g) of the Act, beneficial owners of the reported securities.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not Applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable.


    Item 9.

    Notice of Dissolution of Group

    Not Applicable.

     

    Item 10.

    Certification

    Not Applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    MARAVAI LIFE SCIENCES HOLDINGS, LLC
    By:  

    /s/ Kevin Herde

    Name: Kevin Herde

    Title: Chief Financial Officer

    MARAVAI LIFE SCIENCES HOLDINGS 2, LLC
    By:  

    /s/ Kevin Herde

    Name: Kevin Herde

    Title: Chief Financial Officer

    GTCR FUND XI/C LP

    By: GTCR Partners XI/A&C LP

    Its: General Partner

    By: GTCR Investment XI LLC

    Its: General Partner

    By:  

    /s/ Jeffrey Wright

    Name: Jeffrey Wright

    Title: Chief Legal Officer

    GTCR FUND XI/B LP

    By: GTCR Partners XI/B LP

    Its: General Partner

    By: GTCR Investment XI LLC

    Its: General Partner

    By:  

    /s/ Jeffrey Wright

    Name: Jeffrey Wright

    Title: Chief Legal Officer

    GTCR PARTNERS XI/A&C LP

    By: GTCR Investment XI LLC

    Its: General Partner

    By:  

    /s/ Jeffrey Wright

    Name: Jeffrey Wright

    Title: Chief Legal Officer


    GTCR CO-INVEST XI LP
    By: GRCR Investment XI LLC
    Its: General Partner
    By:  

    /s/ Jeffrey Wright

    Name: Jeffrey Wright
    Title: Chief Legal Officer
    GTCR PARTNERS XI/B LP
    By: GTCR Investment XI LLC
    Its: General Partner
    By:  

    /s/ Jeffrey Wright

    Name: Jeffrey Wright
    Title: Chief Legal Officer
    GTCR INVESTMENT XI LLC
    By:  

    /s/ Jeffrey Wright

    Name: Jeffrey Wright
    Title: Chief Legal Officer


    EXHIBIT LIST

     

    Exhibit A    Joint Filing Agreement, dated as of February 11, 2021, by and among the Reporting Persons (incorporated herein by reference to Exhibit A of the statement on Schedule 13G filed by the Reporting Persons on February 11, 2021).
    Get the next $MRVI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRVI

    DatePrice TargetRatingAnalyst
    2/26/2025$9.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/19/2024Neutral
    Guggenheim
    12/5/2024$4.25Neutral → Sell
    Goldman
    11/14/2024Peer Perform
    Wolfe Research
    11/8/2024Outperform → Mkt Perform
    William Blair
    8/28/2024$10.00Overweight
    Wells Fargo
    8/13/2024$11.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    4/10/2024$15.00Buy
    Craig Hallum
    More analyst ratings

    $MRVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deford John A bought $100,625 worth of shares (17,500 units at $5.75), increasing direct ownership by 33% to 70,046 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/14/24 4:32:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hull Carl bought $987,000 worth of shares (175,000 units at $5.64) (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/12/24 4:59:43 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Financials

    Live finance-specific insights

    See more
    • Maravai Lifesciences Reports First Quarter 2025 Financial Results

      SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, an

      5/12/25 4:06:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.

      5/1/25 7:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne

      3/18/25 4:05:56 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maravai Life Sciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

      2/26/25 7:15:06 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Maravai Life Sciences

      Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral

      12/19/24 8:13:54 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Life Sciences downgraded by Goldman with a new price target

      Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25

      12/5/24 7:46:04 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Asarpota Rajesh was granted 500,000 shares (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/30/25 6:04:51 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Asarpota Rajesh

      3 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/30/25 6:04:27 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Marker Luke Joseph was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:09 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer

      SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh "Raj" Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  "We thank Kevin for his commitment to Maravai and his leadership over the past eight years," said Susannah Gray, Audit Committee Chair, Maravai Board of Directors. "He has played an important role in shaping the company's foundati

      6/25/25 4:01:00 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology

      Quantoom's customers can now access TriLink's CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and ma

      6/3/25 10:00:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    SEC Filings

    See more
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      6/25/25 4:13:09 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      6/9/25 8:40:50 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Maravai LifeSciences Holdings Inc.

      SCHEDULE 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      5/29/25 5:24:04 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer

      SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh "Raj" Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  "We thank Kevin for his commitment to Maravai and his leadership over the past eight years," said Susannah Gray, Audit Committee Chair, Maravai Board of Directors. "He has played an important role in shaping the company's foundati

      6/25/25 4:01:00 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/14/24 7:49:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 4:48:49 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 9:30:19 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care